To compare the reactogenicity and immunogenicity between the two‐dose mRNA COVID‐
19 vaccine regimen and one or two doses of inactivated vaccine followed by an mRNA …

Abstract For SARS-CoV-2 vaccines, efficacy data for BNT162b2 but not CoronaVac are
available in adolescents. Phase II/III studies focused on neutralizing antibody responses in …

In this ongoing study, substantially increased ancestral SARS-CoV-2 neutralizing responses
were observed 1 month after a third 10-µg BNT162b2 dose given to 5 to 11-year olds versus …

Background A primary series of 2-dose SARS-CoV-2 vaccines based on an ancestral strain
generate inadequate neutralizing antibodies against the SARS-CoV-2 Omicron variant. This …

The aim of this study is to investigate the reactogenicity and immunogenicity of the fourth
dose using monovalent mRNA vaccines after different three-dose regimens and to compare …

BACKGROUND AND OBJECTIVES: The messenger RNA (mRNA)-based coronavirus
disease 2019 vaccines approved for use in children< 5 years of age have different antigen …

Objectives Although clinical data have shown that the BNT162b2 vaccine, which is widely
used in many countries, is safe and effective as a protection against the SARS-CoV-2 …

Objectives Clinical evidence on the effectiveness of COVID-19 vaccines for children aged 1–
3 years is scarce. The effectiveness of COVID-19 vaccines was evaluated among non …

Adolescents with underlying diseases are at risk of severe COVID-19. The immune
response of BNT162b2 may be poor among immunocompromised adolescents. We aim to …

Objective Assess real-world effectiveness of vaccines against COVID-19. Methods A test-
negative study was conducted in January-May 2022 during an Omicron BA. 2 wave in Hong …